Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M et al..
2017.
The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations.. J Am Med Inform Assoc. 24(3):513-519.
Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M et al..
2019.
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. Clin Cancer Res. 25(2):573-583.
Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H et al..
2018.
Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.. Mod Pathol. 31(5):791-808.
Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A.
2016.
Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.. Head Neck Pathol. 10(3):394-9.
Nam AS, Kim K-T, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND et al..
2019.
Somatic mutations and cell identity linked by Genotyping of Transcriptomes.. Nature. 571(7765):355-360.